Qatar moves towards genomic and personalised medicine

16 June 2014

Qatar’s Hamad Medical Corporation (HMC) and Duke University in the US are to establish a new Centre for Personalised and Precision Medicine.

Speaking at the inaugural Personalised and Precision Medicine symposium in Doha, HMC Chief of Scientific, Faculty and Academic Affairs Professor Edward Hillhouse said that Qatar’s Academic Health System (AHS) hoped to make personalised medicine an essential component of the healthcare delivery system.  He emphasised that this would mean not only indicidually optimised care based on genetic data, but also population-level disease risk prediction and prevention.

Dr Geoffrey Ginsburg, Director for Genomic Medicine at the Duke Institute for Genome Sciences and Policy, said that the initiative was exciting, adding: “We believe that personalized medicine will increase the efficiency with which healthcare is delivered, optimize efficacy and safety for patients, improve overall population health, and hopefully even reduce cost”.

Qatar is increasingly active in both genomic research and personalised medicine; the symposium was the first of a series intended to contribute to the success of the National Qatar Genome Strategy Project, plans for which were announced late last year.

More from us

Genomics and policy news